Korver et al. also demonstrated that anti-SLAMF6/CD352 antibodies induce complement-dependent cytotoxicity (CDC) primarily in B cells isolated from CLL patients and B lymphoma cell lines. Here, SLAMF6 is linked to B-cell chronic lymphocytic leukemia.